Theodoulou, Elisavet (2023) The role of bone targeted agents in early breast cancer. M.D. thesis, University of Sheffield.
Abstract
Breast cancer is the most common cancer among women with almost 56,000 new cases every year in the UK. Most of the new cases are diagnosed as early breast cancer (EBC) which is potentially curable. However, metastatic disease is the main cause of death in advanced breast cancer. Bone has been identified as the most common site of metastasis in breast cancer and is present in 70% of the patients with metastatic disease.
The bone targeted agents bisphosphonates (BPs) have been extensively investigated for their role in early and metastatic disease. Currently, they have been approved for the following settings:
1) Prevent bone metastasis.
2) Prevention and treatment of cancer treatment-induced bone loss (CTIBL).
3) Management of established bone metastasis.
The main aim of this MD thesis is to describe the role of BPs in EBC and give a better understanding of their use within the UK. Multiple studies have shown that if BPs are given after breast cancer surgery offer anticancer benefits. Nevertheless, these are only in postmenopausal women (natural or induced). The ZOLMENO study, a single centre proof of concept study, was set up with the aim to provide further data for the mechanism responsible for these differential effects of adjuvant BPs. Additionally, the use of these agents in EBC has only recently been approved in the UK, providing the opportunity to track their journey within the UK breast cancer practice. Two surveys (breast cancer oncologists and oncology pharmacists) were conducted with plan to describe the use of adjuvant BPs in the UK. An international collaboration was formed between our team and Australian colleagues where the UK physicians’ adjuvant BPs survey was compared to the Australian physicians’ survey, with the aim to support the adoption of these agents in Australia but also pave the way for other nations to follow the UK example. Also, with the support of Breast Cancer Now (BCN), a UK breast cancer charity, a patients’ survey was performed to gather information about the experience of patients receiving adjuvant BPs.
Early breast cancer therapies are known for their effects on bone health. In particular, antioestrogen treatment with aromatase inhibitors (AIs) have been shown to lead to bone loss and increase the risk of fractures. Subsequently, fragility fractures increase mortality and significantly affect quality of life. Therefore, prevention of CTIBL is crucial, to minimise the risk of fractures among breast cancer patients. This is highly important for older (>70 years) EBC patients where bone density is already negatively affected by age and menopause. With the aim to determine the management of bone health of older women receiving AIs for EBC in the UK, bone health data were collected from the participants of the large multicentre Bridging the Age Gap (BTAG) study .
Metadata
Supervisors: | Holen, Ingunn and Brown, Janet and Wyld, Lynda |
---|---|
Awarding institution: | University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Health (Sheffield) The University of Sheffield > Faculty of Health (Sheffield) > Medicine (Sheffield) |
Academic unit: | Faculty of Medicine, Dentistry and Health. Department of Oncology and Metabolism |
Depositing User: | Dr Elisavet Theodoulou |
Date Deposited: | 03 Jul 2025 11:05 |
Last Modified: | 03 Jul 2025 11:05 |
Open Archives Initiative ID (OAI ID): | oai:etheses.whiterose.ac.uk:36928 |
Downloads
Final eThesis - complete (pdf)
Filename: Theodoulou Elisavet 180254550 MD Thesis.pdf
Licence:
This work is licensed under a Creative Commons Attribution NonCommercial NoDerivatives 4.0 International License
Supplementary Material
Filename: Appendix 2.1 - The Zolmeno study protocol.doc copy.docx
Licence:
This work is licensed under a Creative Commons Attribution NonCommercial NoDerivatives 4.0 International License
Supplementary Material
Filename: Appendix 2.2 - REC approval 16-YH-0151 Fav Conds 13.05.16.pdf
Licence:
This work is licensed under a Creative Commons Attribution NonCommercial NoDerivatives 4.0 International License
Supplementary Material
Supplementary Material
Filename: Appendix 2.4 - sth19171 MHRA approval 11jul16.pdf
Licence:
This work is licensed under a Creative Commons Attribution NonCommercial NoDerivatives 4.0 International License
Supplementary Material
Filename: Appendix 2.5 - SL51 Letter_of_HRA_Approval_20170502.pdf
Licence:
This work is licensed under a Creative Commons Attribution NonCommercial NoDerivatives 4.0 International License
Supplementary Material
Filename: Appendix 2.6 - The Zolmeno study -Patient Information Sheet (PIS).pdf
Licence:
This work is licensed under a Creative Commons Attribution NonCommercial NoDerivatives 4.0 International License
Supplementary Material
Filename: Appendix 4.1 BCN Survey PIS.docx
Licence:
This work is licensed under a Creative Commons Attribution NonCommercial NoDerivatives 4.0 International License
Supplementary Material
Filename: Appendix 5.1 REC approval BTAG sub-study.rtf
Licence:
This work is licensed under a Creative Commons Attribution NonCommercial NoDerivatives 4.0 International License
Supplementary Material
Filename: Appendix 5.2 HRA approval BTAG sub-study.png
Licence:
This work is licensed under a Creative Commons Attribution NonCommercial NoDerivatives 4.0 International License
Supplementary Material
Filename: Appendix 5.3 BTAG - Bone Health in Older Women with EBC - protocol.docx
Licence:
This work is licensed under a Creative Commons Attribution NonCommercial NoDerivatives 4.0 International License
Supplementary Material
Filename: Appendix 5.4 BTAG sub-study CRF.xlsx
Licence:
This work is licensed under a Creative Commons Attribution NonCommercial NoDerivatives 4.0 International License
Export
Statistics
You do not need to contact us to get a copy of this thesis. Please use the 'Download' link(s) above to get a copy.
You can contact us about this thesis. If you need to make a general enquiry, please see the Contact us page.